F-star

For the star type, see F-type main-sequence star.

F-star Biotechnology Ltd. is a biotechnology company, founded in Vienna in 2006,^[1] with a current main research site in Cambridge, UK. The company is focused in developing bispecific monoclonal antibodies using a modular combinatorial approach that engineers the Fc constant region of an immunoglobulin into a novel antigen-binding site.^[2][3]

F-star Biotechnology Ltd.

Industry	Pharmaceutical
Headquarters	Cambridge, UK
Website	www.f-star.com

See also

1. "F-star starts its operations" (PDF). F-Star. 12 June 2006. Retrieved 12 December 2016.
2. "Home". f-star.com.
3. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, Himmler G, Mudde GC, Rüker F (2010). "Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties". Protein Eng Des. 23 (4): 289–297. doi:10.1093/protein/gzq005. PMID 20150180.